Description
Psychological and Behavioral Effects of GLP-1 and GIP Agonists in Weight Loss: A Comprehensive Review This webinar offers a comprehensive overview of the psychological and behavioral effects of GLP-1 and GIP agonists in the management of obesity. The session will explore their impact on appetite control, food-related behaviors, reward mechanisms, and patient motivation. Emerging evidence on mood changes, mental well-being, and adherence in long-term therapy will be discussed. Practical considerations for patient selection, counseling, and monitoring will be highlighted. Designed for healthcare professionals, this webinar aims to support a balanced, holistic approach to pharmacological weight management.
Summary Listen
- Abidizane Metabolic Disorder (AMD), affecting millions globally, represents a significant public health crisis. Approximately 13% of the world's population lives with AMD, with 39% classified as overweight. Projections indicate a substantial rise in obesity prevalence to nearly 24% by 2035, potentially impacting over two billion people.
- Obesity, closely linked to AMD, carries a substantial clinical burden, associated with severe health complications like type 2 diabetes and cardiovascular disease. Psychiatric comorbidities such as depression and anxiety are also highly prevalent, significantly affecting the quality of life for individuals with AMD and obesity.
- D.A.P.1 receptor agonists and duo D.A.P.1 dip agonists have emerged as effective pharmacotherapies for managing obesity and type 2 diabetes. These agents offer potential neuro-behavioral effects, influencing central nervous system pathways involved in appetite regulation, reward processing, mood modulation, and cognitive control.
- The review focuses on elucidating the peripheral and central nervous system mechanisms underlying the psychological effects of D.A.P.1 receptor agonists. It examines their impact on mood, cognition, eating behaviors, and psychiatric safety profiles in clinical populations, while identifying critical knowledge gaps and proposing future research directions.
- The review integrates evidence from clinical trials, neuro-imaging studies, clinical mechanistic investigations, post-market surveillance data, and systematic reviews. It prioritizes clinically relevant and methodologically rigorous studies, focusing on six key areas: CNS mechanisms, mood effects, reward processing, cognitive outcomes, eating behaviors, and psychiatric safety.
- Peripheral mechanisms of D.A.P.1 agonists include gastrointestinal actions, vago-afferent signaling, and metabolic improvements. These mechanisms impact gastric emptying, insulin secretion, gut-brain axis modulation, and metabolic pathways, indirectly influencing mood and cognitive function.
- Neural imaging and behavioral studies suggest D.A.P.1 agonists' involvement in mesolimbic reward circuitry. They demonstrate reduced dopamine signaling, decreased activation in reward-related brain regions, and behavioral shifts toward reduced hedonic drive, resulting in decreased food cravings and emotional eating.
- Emerging evidence suggests GIP-1 receptor agonists may influence mood-related pathways, including hippocampus neurogenesis, reduced neuroinflammation, and modulation of monoaminergic neurotransmission. Psychiatric safety monitoring is crucial due to rare reports of suicidal ideation and potential mood disturbances.
- G.O.P.1 and G.Agonists demonstrate generally favorable safety profiles, but tolerability may influence treatment adherence. Common adverse effects, such as gastrointestinal symptoms, can be mitigated through gradual dose escalation. Careful patient selection and proactive management are essential.
- G.O.P.1 agonists facilitate behavioral changes beyond appetite suppression, including improved dietary adherence, increased motivation for physical activity, and reduced eating disorder symptomatology. They influence appetite through hypothalamic signaling and modulate neuropeptide systems that regulate energy balance.
- Discontinuation of G.A.P.1 agonists can lead to weight regain and diminished metabolic improvements, raising questions about long-term treatment strategies and psychological impact. Research gaps remain regarding long-term psychiatric safety and the durability of behavioral changes. Future research should prioritize well-designed trials, neuro-imaging studies, and investigations into combination therapies.
- D.A.P.1 agonists and dual-japy on-dip agonists present transformative tools for managing obesity and type 2 diabetes. Integrating metabolic and neuro-behavioral domains may redefine obesity treatment as a comprehensive biopsychological model, emphasizing the need for continued investigation to optimize long-term therapy strategies.
Sample Certificate
About the Speakers
Dr. Alisson Barbosa Silva
Professor of Surgery, UNIME School of Medicine, General Surgery, Intensive Care, and Parenteral and Enteral Nutrition Specialist Founder & CEO, Choose Med Academy, Brazil
Comments
Comments
You must be logged in to leave a comment.